<?xml version="1.0" encoding="UTF-8"?>
<p id="p0425">In a retrospective study of patients with leukemia or HCT recipients with PIV infection, ribavirin had no impact on viral shedding, symptom and hospitalization length, progression to lower respiratory tract infection, or mortality.
 <xref rid="bib_45" ref-type="bibr">
  <sup>45</sup>
 </xref> A systematic review evaluated aerosolized or systemic ribavirin in 10 retrospective studies in this same population and found no difference in PIV-associated mortality or in progression to lower respiratory tract infection.
 <xref rid="bib_46" ref-type="bibr">
  <sup>46</sup>
 </xref> Given lack of evidence of clinical efficacy, ribavirin is not recommended for PIV infections. The impact of IVIG alone remains to be determined, although IVIG administration for PIV lower respiratory tract infection did not reduce mortality.
 <xref rid="bib_16" ref-type="bibr">
  <sup>16</sup>
 </xref>
</p>
